XSHE
000566
Market cap877mUSD
Oct 09, Last price
4.71CNY
1D
3.97%
1Q
-4.85%
Jan 2017
-62.94%
Name
Hainan Haiyao Co Ltd
Chart & performance
P/E
—
P/S
7.35
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-17.69%
Revenues
831m
-16.10%
Net income
-430m
L-71.81%
CFO
80m
P
Dividend
Aug 15, 20180.1 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hainan Haiyao Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and medical devices. Its products include cephalosporin series, gastrointestinal series, oncology series, cochlear implant series, active pharmaceutical ingredient (API) series, and intermediate series. The company was founded in 1965 and is headquartered in Haikou, China.
Key people
Jianping Wang
Chairman of the Board · since 2022
Xiufeng Miao
Chief Accounting Officer · since 2025
Yong Tian
Deputy General Manager · since 2025
Wei Wang
Deputy General Manager · since 2025
Lei Shi
Secretary of the Board · since 2025
Duojia Feng
Director · since 2020
Chang Liu
Director · since 2020
Guihao Pan
General Manager, Director · since 2025
Min Wen
Director · since 2024
Xiuqun Hu
Independent Director · since 2023
Independent Director · since 2024
Independent Director · since 2020
Rong Shao
Independent Director · since 2025
Yulin Wei
Independent Director · since 2020
Qiang Zhang
Independent Director · since 2020
Headquarters & legal address
海口市秀英区南海大道192号
海口市, HI 100000
CN
海口市, HI 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||